Brief: Roivant Announces Genevant Sciences’ And Arbutus Biopharma’S $2.25 Billion Global Settlement With Moderna
03/03/2026 21:21
March 3 (Reuters) - Arbutus Biopharma Corp ABUS.O: ROIVANT ANNOUNCES GENEVANT SCIENCES’ AND ARBUTUS BIOPHARMA’S $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA ROIVANT SCIENCES : BOARD APPROVED $1 BILLION SHARE REPURCHASE PROGRAM, INCLUSIVE OF $500 MILLION AUTHORIZATION THAT WAS APPROVED IN JUNE 2025 ROIVANT SCIENCES: UNDER SETTLEMENT, GENEVANT TO GIVE MODERNA NON-EXCLUSIVE LICENSE TO LNP DELIVERY TECHNOLOGY FOR INFECTIOUS DISEASE APPLICATIONS Source text: ID:nGNX8tTKPd Further company coverage: ABUS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple